Piramal Pharma Limited (PPLPHARMA) — Capital Reinvestment Ratio
Piramal Pharma Limited (PPLPHARMA) has a Capital Reinvestment Ratio of 0.49x as of September 2025, meaning it reinvests 0% of its operating cash flow (Rs8.90 Billion) in capital expenditures (Rs4.33 Billion). See Piramal Pharma Limited (PPLPHARMA) balance sheet quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Piramal Pharma Limited Capital Reinvestment Ratio (2021–2026)
This chart tracks Piramal Pharma Limited's Capital Reinvestment Ratio across 6 annual periods. Check PPLPHARMA capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Piramal Pharma Limited (2021–2026)
Year-by-year Capital Reinvestment Ratio for Piramal Pharma Limited from 2021 to 2026. For live market cap and broader valuation context, see Piramal Pharma Limited market capitalisation.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2026 | 0.64x | Rs14.00 Billion | Rs8.90 Billion | ▼ -14.6% |
| 2025 | 0.74x | Rs8.92 Billion | Rs6.64 Billion | ▲ +5.0% |
| 2024 | 0.71x | Rs10.05 Billion | Rs7.12 Billion | ▼ -64.4% |
| 2023 | 1.99x | Rs4.84 Billion | Rs9.65 Billion | ▲ +153.8% |
| 2022 | 0.79x | Rs2.55 Billion | Rs2.01 Billion | ▼ -53.1% |
| 2021 | 1.67x | Rs347.20 Million | Rs581.10 Million | — |